© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Connetics Corp. has received notifications from the FDA that no user fee is required for the new drug application seeking marketing clearance for Extina (ketoconazole 2 percent) Foam. Previously, Connects announced positive results from its Phase III clinical trial with Extina versus Nizoral.